Earnings ·
ARS Pharmaceuticals reported second quarter 2026 financial results, announcing $26.2 million in U.S. neffy net product…
SPRYARS Pharmaceuticals, Inc.
ARS Pharmaceuticals reported second quarter 2026 financial results, announcing $26.2 million in U.S. neffy net product revenue and a total U.S. epinephrine market share of 5%. The company outlined strategic priorities including a shift to targeted provider engagement and significant SG&A cost reductions, aiming for cash flow breakeven by the end of 2027. Interim Phase 2b data for its chronic spontaneous urticaria program is expected in Q1 2027. ARS Pharmaceuticals operates as a biopharmaceutical company commercializing neffy, an epinephrine nasal spray for allergic reactions.